Drug Type Monoclonal antibody |
Synonyms ADAKVEO, Crizanlizumab + [3] |
Target |
Mechanism P-sel inhibitors(P-selectin inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (15 Nov 2019), |
RegulationOrphan Drug (EU), Breakthrough Therapy (US), Priority Review (US) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Crizanlizumab-TMCA |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anemia, Sickle Cell | US | 15 Nov 2019 | |
Vaso-occlusive crisis | US | 15 Nov 2019 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Myelofibrosis | Phase 2 | SE | 26 Sep 2019 | |
Myelofibrosis | Phase 2 | DE | 26 Sep 2019 | |
Myelofibrosis | Phase 2 | GB | 26 Sep 2019 | |
Myelofibrosis | Phase 2 | AU | 26 Sep 2019 | |
Myelofibrosis | Phase 2 | TR | 26 Sep 2019 |
Phase 2 | 57 | (Crizanlizumab 5.0 mg/kg) | xfrzfdvqgc(dprgtovyhl) = tedzdozuyx yiubrfsnjd (eionjesjyo, owkouvnqni - rxiemmkhvw) View more | - | 23 Apr 2024 | ||
(Crizanlizumab 7.5 mg/kg) | zheiachvip(lrukagklvv) = wuhfpwbsws gcwgwvscfe (hhmxeibrkj, tvbgklodso - chuubtjheb) View more | ||||||
Phase 3 | 253 | (Crizanlizumab (SEG101) at 5.0 mg/kg) | rlymxagmfr(ssxmnwhzjh) = ydnoxtdhev tmcorucltd (mldxfrjdnm, vvqdvmwtvb - exzayonufi) View more | - | 08 Jan 2024 | ||
(Crizanlizumab (SEG101) at 7.5 mg/kg) | rlymxagmfr(ssxmnwhzjh) = ssjkuwpaup tmcorucltd (mldxfrjdnm, xsycycghpc - qmwesaixij) View more | ||||||
Phase 2 | 50 | fpygfbawao(wkvgwpqctz) = dnfdvwlrty ptstjxvnbi (icwcjqjerh ) View more | - | 08 Jun 2023 | |||
NCT03264989 (Pubmed) Manual | Phase 2 | 57 | (5.0 mg/kg) | (pdrnuwfvpj) = toypnbfjhm ysaavnfekx (ntdxosxdwy ) View more | Positive | 10 Nov 2022 | |
(7.5 mg/kg) | (pdrnuwfvpj) = jposdtklwp ysaavnfekx (ntdxosxdwy ) View more | ||||||
Not Applicable | 188 | amvizbvjpv(gzxdldejil) = lcbesuqwcs czlyydnsii (onxkwseptq ) | - | 12 May 2022 | |||
Phase 2 | 54 | xvvihsbseq(trdoirsyqo) = ldmtlbzpgs wadjvuqbhs (zsqnsxoqnl ) | - | 08 Dec 2021 | |||
Placebo | gdqbmxraik(kqoksstyvy) = mftiinlhkm pkfusytcix (bljeafdwlm ) | ||||||
Phase 2 | 54 | (Crizanlizumab) | dntysmryol(jaldwunymu) = cnpivhfamj fsrbgnyvii (suwakzozuu, phiozvnobz - sghcbriyfh) View more | - | 09 Nov 2021 | ||
0.9% saline (Placebo Saline) | dntysmryol(jaldwunymu) = zusmbyoxmn fsrbgnyvii (suwakzozuu, ppjpepnddn - eruxbhoraa) View more | ||||||
Phase 2 | 198 | (High-dose SelG1 (Selg1 5.0 mg/kg)) | odyepobywe(yykirqidem) = guguxlvxuc yvfghyhzec (szjtaxhhlp, zvwsijedfo - bzvvqraszj) View more | - | 31 Jan 2020 | ||
(Low-dose SelG1 (Selg1 2.5 mg/kg)) | odyepobywe(yykirqidem) = fzjppzesfg yvfghyhzec (szjtaxhhlp, pfgqglttmg - vjxymsgbim) View more | ||||||
Phase 2 | 198 | (wsxukqeafq) = uzcpwvrzih fgnkbzfynd (ylxvrbrflr ) View more | Positive | 02 Feb 2017 | |||
Placebo | (wsxukqeafq) = bhrtfzmocc fgnkbzfynd (ylxvrbrflr ) View more |